Potential drug-drug interactions among patients with spontaneous intracerebral hemorrhage treated at the Neurological Intensive Care Unit
a single-center experience
DOI:
https://doi.org/10.1590/s2175-97902022220357Keywords:
Drug-drug interactions, Intracerebral hemorrhage, Anticoagulant therapy, Neurological intensive care unitAbstract
Our aim was to determine the prevalence of potential drug-drug interactions (pDDIs) and to identify relevant factors associated with the occurrence of the most dangerous or contraindicated pDDIs (pCDDIs) in hospitalized patients with spontaneous intracerebral hemorrhage (sICH). A retrospective cross-sectional study was performed enrolling all consecutive patients with sICH treated at the Neurological Intensive Care Unit, Clinical Center in Kragujevac, Serbia, during the three-year period (2012-2014). The inclusion criteria encompassed patients aged 18 years and over, those diagnosed with ICH, and those prescribed at least two drugs during hospitalization, while we did not include patients whose hospitalization lasted less than 7 days, those who were diagnosed with other neurological diseases and patients with incomplete medical files. For each day of hospitalization, the online checker Micromedex® software was used to identify pDDIs and classify them according to severity. A total of 110 participants were analysed. A high prevalence of pDDIs (98.2%) was observed. The median number of pDDIs regardless of severity, was 8.00 (IQR 4.75-13.00;1-30). The pairs of drugs involving cardiovascular medicines were the most commonly identified pDDIs. Twenty percent of the total number of participants was exposed to pCDDIs. The use of multiple drugs from different pharmacological-chemical subgroups and the prescribing of anticoagulant therapy significantly increase the chance of pCDDI (aOR with 95% CI 1.19 (1.05-1.35) and 7.40 (1.13-48.96), respectively). This study indicates a high prevalence of pDDIs and pCDDIs in patients with sICH. The use of anticoagulant therapy appears to be the only modifiable clinically relevant predictor of pCDDIs.
Downloads
References
Adane OE, Maxwell OA, Kosisochi CA. Evaluation of drug- drug interactions among chronic kidney disease patients of nephrology unit in the university of Nigeria teaching hospital, Ituku-ozalla, Enugu state. J Basic Clin Pharm. 2017;8:S049-S053.
Aleksic DZ, Jankovic SM, Mlosavljevic MN, Toncev GL, Miletic Drakulic SD, Stefanovic SM. Potential Drug- drug Interactions in Acute Ischemic Stroke Patients at the Neurological Intensive Care Unit. Open Med (Wars). 2019;14:813-26.
Biradar SM, Rajani T, Sravanthi K, Ambali Anand P, Reddy Ch. Srinath, Kalyani NV, et al. Assessment of potential drug-drug interactions in in-patients of a medicine ward of a tertiary care hospital. IJRSB. 2016;5(1):76-82.
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-13.
Busa G, Burlina A, Damuzzo V, Chiumente M, Palozzo AC. Comorbidity, polytherapy, and drug interactions in a neurological context: An example of a multidisciplinary approach to promote the rational use of drugs. J Pharm Pract. 2018;31(1):58-65.
Caratozzolo S, Gipponi S, Marengoni A. Potentially serious drug-drug interactions in older patients hospitalized for acute ischemic and hemorrhagic stroke. Eur Neurol. 2016;76(3-4):161-6.
Castilho ECD, Reis AMM, Borges TL, Siqueira LDC, Miasso AI. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil. J Psychiatr Ment Health Nurs. 2018;25(1):3-13.
Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS. Increased risk of stroke associated with nonsteroidal anti- inflammatory drugs: a nationwide case-crossover study. Stroke. 2010;41(9):1884-90.
Colet CF, Amador TA, Heineck I. Drug Interactions and Adverse Events in a Cohort of Warfarin Users Attending Public Health Clinics. Int J Cardiovasc Sci. 2019;32(2):110-7.
Dastur CK, Yu W. Current management of spontaneous intracerebral haemorrhage. Stroke Vasc Neurol. 2017;2(1):21-9.
Dookeeram D, Bidaisee S, Paul JF, Nunes P, Robertson P, Maharaj VR, et al. Polypharmacy and potential drug- drug interactions in emergency department patients in the Caribbean. Int J Clin Pharm. 2017;39(5):1119-27.
Forbes HL, Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8(10):319-28.
Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charslon Index comorbidity adjustment for ischemic stroke outcome studies. Stroke . 2004;35(8):1941-5.
Hasan SS, Lim KN, Anwar M, Sathvik BS, Ahmadi K, Yuan AW, et al. Impact of pharmacists’ intervention on identification andmanagement of drug-drug interactions in an intensive care setting. Singapore Med J. 2012;53(8):526-31.
Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker BR, Cushman M, Fung GL, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke . 2015;46(7):2032-60.
Jain S, Jain P, Sharma K, Saraswat P. A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit. J Clin Diagn Res. 2017;11(3):FC01-FC04.
Jolink WM, Klijn CJ, Brouwers PJ, Kappelle LJ, Vaartjes I. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. Neurology. 2015;85(15):1318-24.
Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257-63.
Kostic, JM, Zivkovic-Zaric RS, Jankovic SM. Risk factors for potential drug-drug interactions in a general neurology ward. VSP. 2019; Online-First Issue 00, Pages:105-115.
Küppers-Tiedt L, Steiner T. Evidence-based critical care of intracerebral hemorrhage: An overview. Front Neurol Neurosci. 2015;37:27-34.
Kuscu F, Ulu A, Inal AS, Suntur BM, Aydemir H, Gul S, et al. Potential drug-drug interactions with antimicrobials in hospitalized patients: A multicenter point-prevalence study. Med Sci Monit. 2018;24:4240-7.
Lapi F, Piccinni C, Simonetti M, Levi M, Lora Aprile P, Cricelli I, et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med. 2016;11(1):49-59.
Lovenox (R) (enoxaparin sodium solution for subcutaneous and intravenous injection) presribing information. Sanofi- Aventis, Bridgewater, NJ, Dec, 2009. [citad 2020 Sep 23]. Availble from: Availble from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020164s083lbl.pdf
» https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020164s083lbl.pdf
Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061-75.
Murtaza G, Khan MY, Azhar S, Khan SA, Khan TM. Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J. 2016;24(2):220-5.
Okoro R, Farate V. Evaluation of potential drug-drug interactions among patients with chronic kidney disease in northeastern Nigeria. ANJ. 2019;22(1):77-81.
Prabhakaran S, Herbers P, Khoury J, Adeoye O, Khatri P, Ferioli S, et al. Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage? Stroke . 2015;46(2):369-75.
Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Braz J Pharm Sci. 2017;53(1):e16109.
Rosas-Carrasco O, García-Peña C, Sánchez-García S, Vargas-Alarcón G, Gutiérrez-Robledo LM, Juárez-Cedillo T. The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients. Rev Invest Clin. 2011;63(6):564-73.
Shakeel F, Khan JA, Aamir M, Hannan PA, Zehra S, Ullah I. Risk of potential drug-drug interactions in the cardiac intensive care units. A comparative analysis between 2 tertiary care hospitals. Saudi Med J. 2018;39(12):1207-12.
Sharma S, Chhetri HP, Alam K. A study of potential drug- drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol. 2014;46(2):152-6.
Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, et al. Evaluation of a Potential Clinical Interaction between Ceftriaxone and Calcium. Antimicrob Agents Chemother. 2010;54(4):1534-40.
Subramanian A, Adhimoolam M, Kannan S. Study of drug- Drug interactions among the hypertensive patients in a tertiary care teaching hospital. Perspect Clin Res. 2018;9(1):9-14.
Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J. 2014;12:20.
Tesfaye ZT, Nedi T. Potential drug-drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital. Drug Healthc Patient Saf. 2017;9:71-6.
Truven Health Analtytics LLC, Micromedex® Solutions. [citad 2020 Sep 23]. Available from: Available from: https://www.micromedexsolutions.com/home/dispatch/PFDefaultActionId/pf.LoginAction/ssl/true?redirected=true
Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. Stroke . 2016;47(2):356-64.
Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology Am Soc Hematol Educ Program. 2018;2018(1):339-47.
Venkateswaramurthy N, Krishnaveni K, Mercy Freeda R, Sambath Kumar R. Assessment of potential drug-drug interaction in stroke patients. Int J Pharm Pharm Sci. 2016;8(12):221-4.
World Health Organization. Essential medicines and health products. 2. Anatomial Therapeutic Chemical (ATC) Classification. [citad 2020 Sep 23]. Available from: Available from: https://www.who.int/medicines/regulation/medicines-safety/toolkit_atc/en/
» https://www.who.int/medicines/regulation/medicines-safety/toolkit_atc/en/
Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15-27.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Grant numbers 175007
